Skip to main content
. 2018 Mar 30;9(24):16822–16831. doi: 10.18632/oncotarget.24706

Figure 1. Survival based on PET2 evaluation.

Figure 1

Progression-free survival (PFS, A) and overall survival (OS, B) of the 25 patients who had a PET2 evaluation, based on PET positivity (PET+, n = 6) or negativity (PET–, n = 19).